|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 919.80 INR | -0.31% |
|
-1.36% | +0.35% |
| 01-22 | Alivus Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 | CI |
| 01-22 | Alivus Life Sciences Limited, Q3 2026 Earnings Call, Jan 22, 2026 |
| Capitalization | 113B 1.25B 1.05B 958M 915M 1.7B 1.76B 11.14B 4.42B 54.52B 4.67B 4.58B 191B | P/E ratio 2026 * |
20x | P/E ratio 2027 * | 18.1x |
|---|---|---|---|---|---|
| Enterprise value | 109B 1.21B 1.02B 927M 885M 1.64B 1.71B 10.79B 4.28B 52.78B 4.53B 4.43B 184B | EV / Sales 2026 * |
4.25x | EV / Sales 2027 * | 3.82x |
| Free-Float |
23.57% | Yield 2026 * |
1.09% | Yield 2027 * | 1.36% |
Last Transcript: Alivus Life Sciences Limited
| 1 day | -0.31% | ||
| 1 week | -1.36% | ||
| Current month | -4.29% | ||
| 1 month | +4.92% | ||
| 3 months | +1.77% | ||
| 6 months | -4.03% | ||
| Current year | +0.35% |
| 1 week | 910.2 |  | 969.9 |
| 1 month | 819 | | 980 |
| Current year | 819 | | 980 |
| 1 year | 819 | | 1,225.1 |
| 3 years | 370 | | 1,335.1 |
| 5 years | 370 | | 1,335.1 |
| 10 years | 370 | | 1,335.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yasir Rawjee
CEO | Chief Executive Officer | 60 | 12/08/2019 |
| Director of Finance/CFO | - | 31/05/2022 | |
| Compliance Officer | - | 22/02/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Yasir Rawjee
BRD | Director/Board Member | 60 | 12/08/2019 |
Manju Agarwal
BRD | Director/Board Member | 68 | 29/10/2020 |
| Director/Board Member | 66 | 07/01/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.31% | -1.36% | -10.36% | +141.13% | 1.25B | |
| +0.33% | -1.72% | +19.29% | +196.80% | 929B | |
| -0.45% | +1.44% | +54.82% | +49.59% | 587B | |
| +1.76% | +3.61% | +19.67% | +50.59% | 409B | |
| +0.08% | +1.01% | +20.89% | +28.94% | 374B | |
| +1.42% | +7.19% | +26.36% | +32.36% | 320B | |
| +1.08% | +4.32% | +27.98% | +55.61% | 311B | |
| +1.82% | -0.43% | +43.82% | +10.83% | 301B | |
| +1.32% | +5.11% | -45.12% | -37.51% | 219B | |
| +1.52% | -3.94% | +24.32% | +51.52% | 199B | |
| Average | +0.86% | +1.66% | +18.17% | +57.99% | 364.98B | |
| Weighted average by Cap. | +0.75% | +1.58% | +24.98% | +75.77% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 25.72B 284M 239M 218M 208M 387M 402M 2.54B 1.01B 12.42B 1.06B 1.04B 43.41B | 28.19B 311M 262M 239M 228M 424M 440M 2.78B 1.1B 13.61B 1.17B 1.14B 47.58B |
| Net income | 6.3B 69.6M 58.64M 53.49M 51.07M 94.79M 98.49M 622M 247M 3.04B 261M 256M 10.64B | 7.18B 79.25M 66.77M 60.9M 58.15M 108M 112M 708M 281M 3.47B 297M 291M 12.11B |
| Net Debt | -3.59B -39.65M -33.41M -30.47M -29.09M -54M -56.11M -354M -141M -1.73B -149M -146M -6.06B | -5.08B -56.09M -47.26M -43.11M -41.16M -76.4M -79.38M -501M -199M -2.45B -210M -206M -8.57B |
Employees
2,203
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/02/26 | 919.80 ₹ | -0.31% | 53,913 |
| 12/02/26 | 922.65 ₹ | -0.73% | 30,506 |
| 11/02/26 | 929.40 ₹ | -2.35% | 39,127 |
| 10/02/26 | 951.75 ₹ | +1.42% | 55,158 |
| 09/02/26 | 938.40 ₹ | +0.64% | 79,278 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
919.80INR
Average target price
1,214.25INR
Spread / Average Target
+32.01%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALIVUS Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition